**Rhinology**

**Magnetic nanoparticles: a new tool for antibiotic delivery to sinonasal tissues. Results of preliminary studies**

*Nanoparticelle magnetiche: un nuovo strumento per la diffusione degli antibiotici nei tessuti naso-sinusali. Risultati degli studi preliminari*

**K. Dobretsov¹, S. Stolyar³, A. Lopatin²**

¹ Siberian Clinical Center FMBA, Krasnoyarsk, Russia; ² Policlinic №1, Business Administration of the President of Russian Federation, Moscow, Russia; ³ Siberian Federal University, Krasnoyarsk, Russia

**SUMMARY**

Herein we examined the toxicity, penetration properties and ability of Fe₂O₃·nH₂O magnetic nanoparticles extracted from silt of the Borovo Lake (Krasnoyarsk, Russia) to bind an antibiotic. Experimental studies were carried out using magnetic nanoparticles alone and after antibiotic exposure in tissue samples from nasal mucosa, cartilage and bone (*in vitro*). Toxicity of particles was studied in laboratory animals (*in vivo*). Tissues removed at endonasal surgery (nasal mucosa, cartilage and bone of the nasal septum) were placed in solution containing nanoparticles and exposed to a magnetic field. Distribution of nanoparticles was determined by Perls’ reaction. After intravenous injection, possible toxic effects of injected nanoparticles on the organs and tissues of rats were evaluated by histological examination. Binding between the nanoparticles and antibiotic (amoxicillin clavulanate) was studied using infrared spectroscopy. In 30 *in vitro* experiments, magnetisation of Fe₂O₃·nH₂O nanoparticles resulted in their diffuse infiltration into the mucosa, cartilage and bone tissue of the nose and paranasal sinuses. Intravenous injection of 0.2 ml of magnetic nanoparticles into the rat’s tail vein did not result in any changes in parenchymatous organs, and the nanoparticles were completely eliminated from the body within 24 hours. The interaction of nanoparticles with amoxicillin clavulanate was demonstrated by infrared spectroscopy. Positive results of experimental studies provide a basis for further clinical investigations of these magnetic nanoparticles and their use in otorhinolaryngology.

**KEY WORDS:** Nanomedicine • Ferrithydrate nanoparticles • Magnetic field • Antibiotics • Chronic rhinosinusitis

**RIASSUNTO**

Lo studio ha esaminato la tossicità, le proprietà di penetrazione e la capacità di legarsi con un antibiotico delle nanoparticelle magnetiche Fe₂O₃·nH₂O estratte dal limo del lago Borovo (Krasnoyarsk, Russia). Studi sperimentali sono stati effettuati utilizzando nanoparticelle magnetiche da sole e dopo esposizione ad antibiotico su campioni di tessuto di mucosa nasale, cartilagine ed osso (*in vitro*). La tossicità delle particelle è stata studiata su animali da laboratorio (*in vivo*). Tessuti prelevati durante interventi di chirurgia endonasale (mucosa nasale, cartilagine ed osso del setto nasale) sono stati immersi in una soluzione contenente nanoparticelle e poi esposti ad un campo magnetico. La distruzione delle nanoparticelle è stata determinata attraverso la reazione di Perls. Dopo l’iniezione endovenosa, sono stati valutati possibili effetti tossici delle nanoparticelle su organi e tessuti nei ratti mediante esame istologico. Il legame tra nanoparticelle ed antibiotico (amoxicillina clavulanato) è stato studiato utilizzando la spettroscopia ad infrarossi. In 30 esperimenti *in vitro*, la magnetizzazione di nanoparticelle Fe₂O₃·nH₂O ha portato alla loro infiltrazione diffusa nel tessuto muscoso, cartilagineo ed osseo del naso e dei seni paranasali. Con gli sperimenti, si è scoperto che l’iniezione endovenosa di 0.2 ml di nanoparticelle magnetiche nelle vene della coda del ratto non determinava cambiamenti a livello degli organi parenchimatosi, e le nanoparticelle venivano completamente eliminate dall’organismo entro 24 h. L’interazione delle nanoparticelle con amoxicillina clavulanato è stata dimostrata mediante spettroscopia ad infrarossi. I risultati positivi degli studi sperimentali forniscono una base per ulteriori indagini cliniche sulle nanoparticelle magnetiche ed il loro utilizzo in otorinolaringoiatria.

**PAROLE CHIAVE:** Nanomedicina • Ferrithydrate nanoparticelle • Campo magnetico • Antibiotici • Rinosinusite cronica

**Introduction**

The use of new drug formulations is especially important in the treatment of diseases where conventional therapy is not effective. One such example is chronic rhinosinusitis (CRS). According to the European Position Paper on Rhinosinusitis and Nasal Polyp (EPOS, 2012)¹, the prevalence of CRS is increasing annually, and is now one of the most common chronic diseases in humans. For example, in Canada, the prevalence of CRS is 3.4% among men and 5.7% among women², in Belgium it is 6%³ and in Scotland reaches 9.6% of the population⁴.
The ineffectiveness of standard courses of systemic antibiotic therapy \(^5\text{-}^7\), coupled with the doubtful efficacy of corticosteroids, especially in patients with CRS without polyps and concomitant allergy \(^8\text{-}^{10}\), and the inability to achieve 100% success with surgery \(^11\), indicate the need to develop newer and more effective treatment modalities. Magnetic nanoparticles as a targeted drug delivery tool for the tissues of nose and paranasal sinuses in CRS are a promising research direction.

Materials and methods

To determine penetration of magnetic nanoparticles in tissues, samples of nasal mucosa were taken from the ethmoidal labyrinth cells during functional endoscopic surgery, while cartilage and bone of the nasal septum were obtained during nasal septal surgery. The indications for nasal surgery were nasal obstruction secondary to CRS and significant nasal septal deformity.

For controlled delivery of nanoparticles in tissues, an external magnetic field device for low-frequency magnetic therapy “Pole 101” (EMA Factory, Yekaterinburg, Russia) ensuring continuous operation of one inductor with a magnetic field gradient of 4.6 mT/mm and magnetic induction 10.14-19.56 mT was used.

The study drug was prepared as follows: 0.125 grams of magnetic nanoparticles were diluted in 1 ml of normal saline (sterile 0.9% NaCl). The material was equally divided into three groups (20 experiments in each group).

In group 1, mucosa, cartilage and bone tissue samples were placed in a flask with dispersed nanoparticles in normal saline for 20 minutes, washed in saline and sent for histological examination. In Groups 2 and 3, the same tissue samples were immersed in a flask with dispersed nanoparticles in normal saline and kept in a magnetic field produced by the device “Pole-101” for 20 and 40 min, respectively, before rinsing in saline and sent for histological examination.

For identification of the presence of nanoparticles in tissue samples, a specific reaction for detecting iron (reaction to Berlin blue or Perls’ reaction) was used. Therefore, tissue sections remained in 1% hydrochloric acid solution and after rinsing in distilled water they were stained again with aluminous carmine, rinsed in water and carried through ethanol, xylene and carbol-xylene. Iron deposits were coloured dark blue. After staining, tissue samples were studied under a light microscope at magnifications of ×100 and ×200.

To investigate the potential toxicity of magnetic nanoparticles, parenchymatous organs of laboratory animals (rats) were selected. Over a 10 day period, 0.2 ml of magnetic nanoparticles dissolved in distilled water were injected into the tail vein of rats (n = 10) every other day. Weight changes during drug administration as well as the animals’ eating habits were controlled daily. After 12 days, all rats were euthanised under general anaesthesia in accordance with GLP principles of euthanasia. To determine changes in investigated organs, morphological examination assessing macroindicators was carried out. Tissue biopsies were fixed in 10% formalin solution. Slices of 5-7 µm thickness were stained with haematoxylin followed by microscopic examination of the material at magnifications of ×100 and ×200. All animal experiments were carried out in accordance with the requirements and provisions outlined in the Declaration of Helsinki of the World Medical Association (2000) and the local ethics committee approved the final study protocol.

Given the fact that magnetic nanoparticles of ferrihydrite are biologically neutral and may bind drugs by either covalent bonding or simple adsorption, nanoparticles were mixed with the antibiotic amoxicillin clavulanate. To confirm binding, infrared spectroscopy was used. For this purpose, powder of 1.2 g of amoxicillin clavulanate was added to 5 ml of a solution of ferrihydrite nanoparticles and magnetised in the magnetic therapy machine “Magofon-01” (Elatomsk Instrument Plant, Elatma, Russia) with a magnetic induction of 30 ± 9 mT and a frequency of acoustic range 0.02-20 kHz for...

Fig. 1. Histological picture of the respiratory epithelium: a) nanoparticles (indicated by arrow) are located on the mucous membrane (Group 1); b) nanoparticles (indicated by arrows) after magnetic action, located in the nasal mucosal and submucosal layers of epithelium. Perls’ reaction. ×100.
5 min, and placed in a liquid reservoir with BaFe<sub>2</sub> glasses of 0.1 mm thickness. Infrared spectrum was recorded at room temperature using Nicolet-6700 (Thermo Scientific, USA) in the range from 1100 to 2800 cm<sup>-1</sup> (Group 1). A similar study was conducted with 1.2 g of amoxicillin clavulanate powder dissolved in 5 ml of ferrihydrite nanoparticles without magnetic action (Group 2) as well as with 1.2 g of amoxicillin clavulanate powder dissolved in 5 ml of water without nanoparticles (Group 3). Each group was studied with 10 identical experiments.

Results

Tissue penetration of nanoparticles (nasal mucosa and nasal septum cartilage and bone morphology)
The study of penetration of magnetic nanoparticles in tissues of the nose showed that in Group 1 nanoparticles did not penetrate deeply into the nasal mucosa, but were found only on the surface of epithelium (Fig. 1a). In addition, despite the relatively loose structure of the nasal septal cartilage, without exposure to a magnetic field, nanoparticles were located on the edge of cartilage (Fig. 2a). A similar pattern was also observed in the bone tissue of the nasal septum. Coloured nanomaterial was located mainly in the lumen and around the bony canals. Ferruginous substance did not penetrate into the bone tissue (Fig. 3a).

Following the exposure of tissues to a magnetic field for 20 min (Group 2), the activity of iron-containing nanoparticles increased substantially. As a result, magnetic nanoparticles were located in the epithelium and subepithelial layer of the nasal mucosa and also sporadically dispersed (Fig. 1b). In addition, under the influence of a magnetic field gradient, nanoparticles freely penetrated into the body of the nasal septal cartilage (Fig. 2b) and were diffusely distributed. The same pattern was observed in bone tissue of the nasal septum where the nanoparticles penetrated throughout bone fragments (Fig. 3b). After doubling exposure time to the magnetic field (Group 3), there was no significant increase in the concentration of iron compounds in tissues.
In vivo analysis of nanoparticle injection in a rat model

To assess toxicity of the magnetic nanoparticles, laboratory animals (rats, n = 10) treated with nanoparticles were followed for 10 days and then examined histologically. Global vital parameters of the experimental animals, i.e. medium body weight, did not change significantly and eating habits remained the same over the time of observation.

Animal liver tissue. Microscopic examination revealed that the lobular-girder structure of the liver was preserved. Hepatic lobule, sinusoidal capillaries, blood vessels and bile ducts displayed normal structure in all animals. Moderate polymorphism of hepatocytes and their nuclei was observed. The cytoplasm of investigated cells was stained uniformly. Kupffer and endothelial cells had normal shape; their hyperchromic nuclei were properly located. Perls’ reaction did not demonstrate any presence of iron nanoparticles in liver tissue.

Animal kidney tissue. Renal glomeruli demonstrated normal structure. Capillary loops of some glomeruli were collapsed, and nuclei were elongated. Epithelium of renal tubules was structurally normal. Clear brush rim was observed in the proximal tubules, and the lumen had normal width. Collecting glomeruli had a normal shape and contained dark and light epithelial cells. Magnetic nanoparticles in tissues of the kidney, as well as in the liver, were not detected.

Animal lung tissue. No pathological changes were observed in lung tissue. Bronchi were lined with ciliated epithelium. Peribronchial accumulations of lymphoid cells with the formation of solitary lymphoid follicles were noted. The pulmonary vascular bed was anaemic. Alveoli were well inflated; small foci of atelectases were found. In Perls’ reaction, nanoparticles in the lung tissue were not present.

Table I. Experimental studies on magnetic nanoparticles Fe₃O₄·nH₂O.

| Purpose | Methods | Result | Conclusion |
|---------|---------|--------|------------|
| I Investigation of penetration ability of Fe₃O₄·nH₂O nanoparticles into human tissues | Tissue samples (mucosa, cartilage and bone tissue of the human nose) were kept in a flask with dispersed nanoparticles in normal saline under the action of a magnetic field or without it | Magnetisation of nanoparticles for 20 min results in their diffuse infiltration into the mucous membrane, cartilage and bone tissue | Ability to control distribution of the nanoparticles in the humans nasal mucosa, bone and cartilage by an external magnetic field |
| II Assessment of the toxicity of magnetic nanoparticles in laboratory animals | Injection of magnetic nanoparticles dissolved in distilled water into the tail vein of rats (N = 10) over a 10-day period followed by morphological examination of tissue biopsies | No pathological changes in the parenchymatous tissues (liver, kidney, and lung). Complete clearance of nanoparticles from the body within days | Magnetic nanoparticles are nontoxic |
| III Investigation of the ability of magnetic nanoparticles to interact and bind with an antibiotic | Infrared spectroscopy: a magnetised solution of amoxicillin clavulanate mixed with ferrhydrite nanoparticles (Group 1), an amoxicillin clavulanate + nanoparticles solution without previous magnetic action (Group 2) and an amoxicillin clavulanate solution alone (Group 3) | The change of the absorption spectrum of magnetised complex ferrhydrite/amoxicillin clavulanate at the range of 1650-1670 cm⁻¹ | Formation of a complex nanoparticles + antibiotic by hydrogen bonds or weak induction forces |

Conjugation of nanoparticle to antibiotic

When comparing the results of infrared spectroscopy of the complex nanoparticle/amoxicillin clavulanate without magnetic action and conventional aqueous amoxicillin clavulanate, no significant differences were found. However, after introduction of the complex into magnetic field, there was sharp decrease in absorption at 1650-1670 cm⁻¹ with the appearance of additional bands at 1558.6 and 1540.9 cm⁻¹ (Fig. 4a-b).

Results of all experimental studies conducted are summarised in Table I.

Discussion

One of the most rapidly developing and promising fields of scientific research to date is nanotechnology. This technology explores the properties and practical applications of nanoparticles which are extremely small in size.
(a few nm); a variety of physical and chemical substances have been examined: silicon, gold, zinc, iron, aluminosilicates, ferromagnetic and diamagnetic materials.\textsuperscript{14,15}

The most promising direction for nanotechnology in medicine is the use of magnetic nanoparticles as carriers of drugs (vehicles). This is due to the ability of drugs immobilised on the surface of magnetic nanoparticles to selectively concentrate and move under the influence of an external magnetic field in a specific body area.\textsuperscript{16-18}

In 2006, magnetic nanoparticles of bacterial origin were developed in the Institute of Biophysics (Siberian Branch of the Russian Academy of Science, Krasnoyarsk, Russia). They were synthesised by cultivating gram-negative bacilli from the Enterobacteriaceae family (genus \textit{Klebsiella}, type \textit{Klebsiella oxytoca}) isolated from silt (sapropel) of the lake Borovoye, Krasnoyarsk District, Russia. Based on comparison of the results of magnetic and direct structural methods, the resulting magnetic nanoparticles are ferrihydrite $\text{Fe}_2\text{O}_3\cdot n\text{H}_2\text{O}$ as seen in Figure 5. It was also demonstrated that the ferrihydrite nanoparticles 2-5 nm in size produced by \textit{Klebsiella oxytoca} have an effective magnetic charge enabling magnetic control of these nanoparticles.\textsuperscript{13}

Ferrihydrite nanoparticles produced by \textit{Klebsiella oxytoca} possess unique magnetic properties in the biomineralisation of natural iron salt solutions. Antiferromagnetic order inherent in the massive ferrihydrite and spontaneous magnetic moment due to decompensation of the spins in the sublattices coexists in these nanoparticles. Enhanced by the effect of superantiferromagnetism, the magnetic susceptibility enabled magnetic control of these materials.

Intravenous injection of magnetic nanoparticles in laboratory animals (rats) for 10 days caused no pathological changes in the parenchymatous tissues (liver, kidney, and lung). Absence of changes in the kidney histological architecture of these animals demonstrates that these magnetic nanoparticles were nontoxic. In addition, the study showed complete clearance of nanoparticles from the animals’ body within days, characterised by negative Perls’ reaction in all animal tissues studied.

The study of magnetic nanoparticles penetration into nasal tissues \textit{in vitro} showed that the effect of an external magnetic field for 20 min resulted in a diffuse distribution of nanoparticles in mucosa, cartilage and bone tissue of the human nose. Therefore, the possibility of targeted delivery of nanoparticles into the lamina propria of the nasal respiratory epithelium is especially important in the treatment of CRS when chronic inflammation affects primarily the mucous membrane of the nose and paranasal sinuses. Penetration of iron nanoparticles into tissues confirmed their magnetic reactivity and strongly suggests that these iron nanoparticles can be controlled by an external magnetic field.

Although there is an absence of evidence-based literature that topical application of antibiotics is effective in the treatment of CRS, bacteria are believed to universally present in CRS. Certain bacteria likely influence mucosal inflammation in the paranasal sinuses contributing to CRS persistence and severity.\textsuperscript{19,20} Under certain circumstances, at least in case of acute exacerbation, antibiotics can ameliorate the severity of CRS. Dependence of treatment outcome on contamination of the sinuses with bacteria like \textit{S. aureus}, and the need for pathogen eradication has been also stressed.\textsuperscript{21} However, the current options in topical antimicrobial therapy and methods for delivery of antimicrobial agents to the paranasal sinuses are few at best.\textsuperscript{22-24} Therefore, our first step toward future clinical implications of the new method of drug delivery was investigation of possible conjugation of a nanoparticle to antibiotic.

Preliminary results of our study have shown that the antibiotic molecule readily links with nanoparticles. Infrared spectrometry revealed the change of the absorption spectrum of magnetised complex ferrihydrite/amoxicillin clavulanate, which reliably indicates the formation of bonding between the initial reagents with participation of either hydrogen bonds or weak induction forces.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{Fig5.png}
\caption{Magnetic nanoparticles Fe$_2$O$_3$: a) scanning tunnelling microscopy, $\times 20$ nm; b) schematic drawing of Fe-O-Fe links in a non-defect phase: smaller grey balls, O and OH ligands; larger grey balls, Fe$^{3+}$.}
\end{figure}
Conclusions
We believe that the initial results of these experimental studies provide a rational basis for development of a new method of targeted drug delivery to tissues of the nose and paranasal sinuses. Further experimental and clinical investigations of magnetic Fe₂O₃ nanoparticles linked with an antibiotic, glucocorticosteroids, or some other agents are needed, as they can considerably improve our therapeutic options in treatment of chronic inflammation of the sino-nasal mucosa.

Acknowledgements
This study was supported by the Federal Target Program “Research and scientific-teaching staff in innovative Russia” in 2009-2013.

References
1. Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol 2012;23(Suppl 1):1-298.
2. Chen Y, Dales R, Lin M. The epidemiology of chronic rhinosinusitis in Canadians. Laryngoscope 2003;113:1199-205.
3. Gordts F, Clement PAR, Buisseret T. Prevalence of sinusitis signs in a non-ENT population. Otorhinolaryngology 1996;58:315-9.
4. Ahsan SF, Jumans S, Nunez DA. Chronic rhinosinusitis: a comparative study of disease occurrence in North of Scotland and Southern Caribbean otolaryngology outpatient clinics over a two month period. Scott Med J 2004;49:130-3.
5. Legent F, Bordure P, Beauvillain C, et al. A double-blind comparison of ciprofloxacin and amoxycillin/clavulanic acid in the treatment of chronic sinusitis. Chemotherapy 1994;40(Suppl 1):8-15.
6. Namyslowski G, Misiolek M, Czeckor E, et al. Comparison of the efficacy and tolerability of amoxicillin/clavulanic acid 875 mg bid with cefuroxime 500 mg b.i.d. in the treatment of chronic and acute exacerbation of chronic sinusitis in adults. J Chemother 2002;14:508-17.
7. Soler ZM, Oyer SL, Kern RC, et al. Antimicrobials and chronic rhinosinusitis with or without polyposis in adults: an evidenced-based review with recommendations. Int Forum Allergy Rhinol 2013;3:31-47.
8. Parikh A, Scadding GK, Darby Y, et al. Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology 2001;39:75-9.
9. Giger R, Pasche P, Cheseaux C, et al. Comparison of once-versus twice-daily use of beclometasonedipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis. Eur Arch Otorhinolaryngol 2003;260:135-40.
10. Dijkstra MD, Ebbens FA, Poublon RML, et al. Fluticasone propionate aqueous nasal spray does not influence the recurrence rate of chronic rhinosinusitis and nasal polyps 1 year after functional endoscopic sinus surgery. Clin Exp Allergy 2004;34:1395-400.
11. Lund VJ. Evidence-based surgery in chronic rhinosinusitis. Acta Otolaryngol 2001;121:5-9.
12. Vasilyev AE. Nanocarriers of the drugs. New Pharmacy 2003;1:64-7.
13. Kreuter J. Nanoparticles - a historical perspective. Int J Pharm 2007;333:1-10.
14. Bondar BC, Pozdnyakova IO, Puzyr AP. Application of nanodiamonds for separation and purification of proteins. Solid State Physics 2004;4:737-9.
15. Hernando A, Crespo P, Garcia MA. Metallic magnetic. ScientificWorldJournal 2005;5:972-1001.
16. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005;26:3995-4021.
17. Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application. Angew Chem Int Ed Engl 2007;46:1222-44.
18. Yao L, Xu S. Long-range, high-resolution magnetic imaging of nanoparticles. Angew Chem Int Ed Engl 2009;48:5679-82.
19. Abreu NA, Nagalingam NA, Song Y, et al. Sinus microbiome diversity depletion and Corynebacterium tuberculosisenrichment mediate rhinosinusitis. Sci Transl Med 2012;4(151):151ra124.
20. Boase S, Foreman A, Cleland E, et al. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biofilm detection. BMC Infect Dis 2013;13:210.
21. Liu CM, Soldanova K, Nordstrom L, et al. Medical therapy reduces microbiota diversity and evenness in surgically recalcitrant chronic rhinosinusitis. Int Forum Allergy Rhinol 2013;3:775-81.
22. Kobayashi T, Baba S. Topical use of antibiotics for paranasal sinusitis. Rhinology 1992;14(Suppl):1-10.
23. Desrosiers MY, Salas-Prato M. Treatment of chronic rhinosinusitis refractory to other treatments with topical antibiotic therapy delivered by means of a large particle nebulizer: results of a controlled trial. Otolaryngol Head Neck Surg 2001;125:265-9.
24. Viderer WJ, van Drunen CM, Reitsma JB, et al. Nebulized bacitracin/colimycin: a treatment option in recalcitrant chronic rhinosinusitis with Staphylococcus aureus? A double blind, randomized, placebo-controlled, cross-over pilot study. Rhinology 2008;46:92-8.

Received: July 26, 2014 - Accepted: October 11, 2014